A serological assay to detect SARS-CoV-2 seroconversion in humans

Fatima Amanat[1,2], Thi H.O. Nguyen[3], Veronika Chromikova[1], Shirin Strohmeier[1,4], Daniel Stadlbauer[1], Andres Javier[1], Kaijun Jiang[1], Guha Asthagiri Arunkumar[1,2], Jose Polanco[1,5], Maria Bermudez-Gonzalez[1], Daniel Caplivski[6], Allen Cheng[7], Katherine Kedzierska[3], Olli Vapalahti[8,9,10], Jussi M. Hepojoki[8,11], Viviana Simon[1,12,13] and Florian Krammer[1]*

[1]*Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA*
[2]*Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA*
[3]*Department of Microbiology & Immunology, University of Melbourne, The Peter Doherty Institute for Infection & Immunity, Melbourne, Victoria, Australia*
[4]*Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria*
[5]*Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA*
[6]*Travel Medicine Program, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA*
[7]*School of Public Health and Preventive Medicine, Monash University; Infection Prevention and Healthcare Epidemiology Unit, Alfred Health*
[8]*Department of Virology, Medicum, University of Helsinki, Helsinki, Finland*
[9]*Veterinary Biosciences, Veterinary Faculty, University of Helsinki, Helsinki, Finland*
[10]*Department of Virology and Immunology, Helsinki University Hospital (HUSLAB), Helsinki, Finland*
[11]*Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland*
[12]*Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, NY, USA*
[13]*Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA*

*To whom correspondence should be addressed: florian.krammer@mssm.edu

Abstract

Introduction: SARS-Cov-2 (severe acute respiratory disease coronavirus 2), which causes Coronavirus Disease 2019 (COVID19) was first detected in China in late 2019 and has since then caused a global pandemic. While molecular assays to directly detect the viral genetic material are available for the diagnosis of acute infection, we currently lack serological assays suitable to specifically detect SARS-CoV-2 antibodies.

Methods: Here we describe serological enzyme-linked immunosorbent assays (ELISA) that we developed using recombinant antigens derived from the spike protein of SARS-CoV-2. These assays were developed with negative control samples representing pre-COVID 19 background immunity in the general population and samples from COVID19 patients.

Results: The assays are sensitive and specific, allowing for screening and identification of COVID19
seroconverters using human plasma/serum as early as 3 days post symptom onset. Importantly, these
assays do not require handling of infectious virus, can be adjusted to detect different antibody types and
are amendable to scaling.

Conclusion: Serological assays are of critical importance to determine seroprevalence in a given
population, define previous exposure and identify highly reactive human donors for the generation of
convalescent serum as therapeutic. Sensitive and specific identification of Coronavirus SARS-Cov-2
antibody titers will also support screening of health care workers to identify those who are already
immune and can be deployed to care for infected patients minimizing the risk of viral spread to
colleagues and other patients.

Introduction

On December 31st, 2019 China reported first cases of atypical pneumonia in Wuhan, the capital of Hubei
province. The causative virus was found to be a betacoronavirus, closely related to the severe acute
respiratory syndrome coronavirus (SARS-CoV-1) from 2003 and similar to *Sarbecoviruses* isolated from
bats.[1,2] It was therefore termed SARS-CoV-2 and the disease it causes was named COVID19 (COronaVIrus
Disease 2019).[3] The outbreak in Wuhan expanded quickly and led to the lockdown of Wuhan, the Hubei
province and other parts of China. While the lockdown, at least temporarily, brought the situation under
control in China, SARS-CoV-2 spread globally causing a pandemic with, so far, 150,000 infections and
5,500 fatalities (as of March 16th, 2020).

Nucleic acid tests that detect the SARS-CoV-2 RNA genome were quickly developed and are now widely
employed to diagnose COVID19 disease.[4,5] However, there remains a great need for laboratory assays
that measure antibody responses and determine seroconversion. While such serological assays are not
well suited to detect acute infections, they are support a number of highly relevant applications. First,
serological assays allow us to study the immune response(s) to SARS-CoV-2 in dynamic qualitative and
quantitative manner. Second, serosurveys are needed to determine the precise rate of infection in an
affected area, which is an essential variable to accurately determine the infection fatality rate. Third,
serological assays will allow for the identification of individuals who mounted strong antibody responses
and who could serve as donors for the generation of convalescent serum therapeutics. Lastly, serological
assays will permit to determine who is immune and who is not. This would be very useful for deploying
immune healthcare workers in a strategic manner as to limit the risk of exposure and spread of the virus
inadvertently.

Sarbecoviruses express a large (approximately 140 kDa) glycoprotein termed spike protein (S, a
homotrimer), which mediates binding to host cells via interactions with the human receptor angiotensin
converting enzyme 2 (ACE2).[6-8] The S protein is very immunogenic with the receptor-binding domain
(RBD) being the target of many neutralizing antibodies.[9] Individuals infected with coronaviruses typically
mount neutralizing antibodies, which might be associated with some level of protection for a period of
months to years, and neutralizing response has demonstrated for SARS-CoV-2 in an individual case from
day 9 onwards.[10-13] Serum neutralization can be measured using live virus but the process requires
several days and must be conducted under biosafety level 3 laboratory containment for SARS-CoV-2
Potentially, pseudotyped viral particle entry assays based on lentiviruses or vesicular stomatitis virus can

be used as well, but these reagents are not trivial to produce. A simple solution is the use of a binding
assay, e.g. an enzyme linked immunosorbent assays (ELISA), with recombinantly expressed antigen as
substrate. Here we report the development of such an assay and provide a protocol for both
recombinant antigen production as well as the ELISA.

Results

Expression constructs and generation of recombinant SARS-Cov-2 proteins

We generated two different versions of the spike protein. The first construct expresses a full length
trimeric and stabilized version of the spike protein and the second only the much smaller receptor
binding domain (RBD). The sequence used for both proteins is based on the genomic sequence of the
first virus isolate, Wuhan-Hu-1, which was released on January 10th 2020.[1] Sequences were codon
optimized for mammalian cell expression. The full-length spike protein sequence was modified to
remove the polybasic cleavage site, which is recognized by furin and to add a pair of stabilizing
mutations (**Figure 1**).[7,14,15] These two modifications were included to enhance the stability of the protein
based on published literature.[7,14] At amino acid P1213 the sequence was fused to a thrombin cleavage
site, a T4 foldon sequence for proper trimerization and a C-terminal hexahistidine tag for purification
(**Figure 1**).[16,17] The sequence was cloned into a pCAGGS vector for expression in mammalian cells and
into a modified pFastBac Dual vector for generation of baculoviruses and expression in insect cells. For
expression of the RBD, the natural N-terminal signal peptide of S was fused to the RBD sequence (amino
acid 419 to 541) and joined with a C-terminal hexahistidine tag.[18] The same vectors as for the full length
S protein were used to express the RBD. In mammalian cells, the RBD domain gave outstanding yields
(approximately 25 mg/liter culture), but expression was lower in insect cells (approximately 0.4 mg/liter
culture). Clear single bands were visible when the recombinant RBD proteins were analyzed on a
reducing sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), with the insect cell
derived protein (iRBD) running slightly lower than the mammalian cell derived protein (mRBD) (**Figure
1**). The size difference likely reflects differences in glycan sizes between insect cells and mammalian
cells. The full-length S protein was expressed in both systems with slightly higher yields in mammalian
cells (mSpike) than in insect cells (iSpike) (approximately 2 mg/liter cultures versus 0.5 mg/liter culture).
The full-length protein appeared as a double band on a reducing SDS-PAGE, the higher species likely
being the full-length protein and the slightly lower species likely a cleavage product.

ELISA development

We used a panel of 59 banked human serum samples collected from study participants including
participants with confirmed previous viral infections (e.g., hantavirus, dengue virus, coronavirus NL63 –
sample take 30 days post symptom onset) to establish an ELISA with these proteins. These human sera
were used to test the background reactivity to the SARS-CoV-2 spike in the general US population
covering an age range from approximately 20 to 65+ years. Four plasma/serum samples from three
COVID19 patients were used to determine the reactivity of SARS-CoV-2 infected individuals to the RBD
and the full length spike.

ELISAs were performed by doing serial dilution of the individual serum samples. Values from the dilution
curves were used to determine the area under the curve (AUC), which was graphed. All COVID10
plasma/serum samples reacted strongly to both RBD and full-length spike protein while reactivity of the
other serum samples only yielded background reactivity (**Figure 2**). Reactivity of COVID19 sera was, in
general, stronger against the full-length S protein than against the RBD, likely reflecting the higher
number of epitopes found on the much larger spike protein. For the RBD the difference between
control sera and convalescent sera was larger when the insect cell derived protein was used as
compared to the mammalian cell derived RBD. The same was true for the full-length spike protein. The
assay allowed to clearly distinguish the convalescent sera from the banked control sera.

Antibody isotyping and subtyping

For the four COVID19 patient plasma/sera, we also performed an isotyping and subtyping ELISA using
the insect cell and mammalian cell expressed S proteins. Strong reactivity was found for all samples for
IgG3, IgM and IgA (**Figure 3**). An IgG1 signal was also detected for three out of the four samples, while
one sample showed no reactivity. No signal was detected for IgG4 and reagents for IgG2 were
unavailable.

Discussion

Here we describe a serological method to detect seroconversion upon SARS-CoV-2 infection. The
method is based on reactivity to the immunogenic S protein of the virus. It is relatively simple and quick
in its execution and can be performed at biosafety level 2 level as it does not involve life virus. We have
tested these methods using banked serum samples obtained from study participants in 2019 and early
2020 when this virus was not widely circulating in the US. These serum samples produced low, close to
baseline signals in our ELISA. Since the age range of the participants was broad, ranging from to 65+
years of age, it is likely that most had experienced infections with human coronaviruses including the
alphacoronaviruses NL63 and 229E as well as the betacoronaviruses OC43 and HKU1. We included
paired serum samples (acute and convalescent) from a participant with a laboratory confirmed
coronvirus NL63 infection. Our data show that there is no or only negligible cross-reactivity from human
coronaviruses to SARS-CoV-2. Of note, even infection with the human alphacoronavirus NL63, which
also uses ACE2 as receptor[19], did not induce cross-reactivity. This is of great importance because it
suggests that humans are completely naïve to SARS-CoV-2, which may explain the relatively high R_0 of
SARS-CoV-2 compared to other respiratory viruses such as influenza virus.[20] It might also suggest that
antibody-dependent enhancement from human coronavirus induced cross-reactive antibodies targeted
at the S protein is unlikely to be the cause of the high pathogenicity of the virus in humans.[21]

The plasma/sera used in this study from patients with COVID19 were obtained at day 20 (SARS-CoV2
#1), at day 4 (SARS-CoV-2 #2), days 2 and 6 (SARS-CoV-2 #3A and B) post symptom onset. Our data
shows significant seroconversion after natural infection with SARS-CoV-2. Our results suggest that
antibodies mounted upon infection target the full length S protein as well as the RBD, which is the major
target for neutralizing antibodies for related viruses coronaviruses.[9] In fact, sample SARS-CoV2 #1 was
tested in another study in neutralization assays and showed a neutralizing titer of 1:160.[13] Thus,

seroconversion may lead to protection at a minimum for a limited time. Interestingly, the IgG3 response
was stronger than the IgG1 response which is in contrast to e.g. the immune response to influenza
where usually IgG1 responses dominates.[22,23] Lastly, we also detected strong IgA and IgM responses in
the blood compartment. Of note, level of reactivity and antibody isotypes matched expected patterns
based on time since symptom onset very well.

We believe that our ELISA method will be key for serosurveys aimed at determining the real attack rate
and infection fatality rate in different human populations and to map the kinetics of the antibody
response to SARS-CoV-2. In addition, clinical trials with convalescent serum as therapeutic have been
initiated in China (e.g. NCT04264858) and anecdotal evidence from the epidemic in Wuhan suggests that
compassionate use of these interventions was successful. China has recently shipped convalescent sera
to Italy for use in patients and efforts to produce convalescent serum batches are ongoing in the US as
well. Screening sera using our assay would be faster and easier than performing standard neutralization
assays in BSL3 containment laboratories. Patients recovering from COVID19 disease could be screened
for strong antibody responses using the assays described here, especially the one using the RBD as
substrate since anti-RBD antibodies likely correlate with virus neutralization. In addition, the assay could
be used to screen health care workers to allow selective deployment of immune medical personnel to
care for patients with COVID19. Such a strategy would likely limit nosocomial spread of the virus. Of
course, the generated recombinant proteins are also excellent reagents for vaccine development and
can serve as baits for sorting B cells for monoclonal antibody generation. We are making the methods
and laboratory reagents widely available to the research community in order to support the global effort
to limit and mitigate spread of SARS-CoV-2.

Methods

Recombinant proteins
The mammalian cell codon optimized nucleotide sequence coding for the spike protein of SARS-CoV-2
isolate (GenBank: MN908947.3) was synthesized commercially (GeneWiz). The receptor binding
domain (RBD, amino acid 319 to 541, RVQP....CVNF) along with the signal peptide (amino acid 1-14,
MFIF....TSGS) plus a hexahisitidine tag was cloned into mammalian expression vector pCAGGS as well as
in a modified pFastBacDual vectors for expression in baculovirus system. The soluble version of the spike
protein (amino acids 1-1213, MFIF....IKWP) including a C-terminal thrombin cleavage site, T4 foldon
trimerization domain and hexahistidine tag was also cloned into pCAGGS. The protein sequence was
modified to remove the polybasic cleavage site (RRAR to A) and two stabilizing mutations were
introduced as well (K986P and V987P, wild type numbering). Recombinant proteins were produced
using the well-established baculovirus expression system and this system has been published in great
detail in [16,24,25] including a video guide. Recombinant proteins were also produced in Expi293F cells
(ThermoFisher) by transfections of these cells with purified DNA using ExpiFectamine 293 Transfection
Kit (ThermoFisher). Supernatants from transfected cells were harvested on day 3 post-transfection by
centrifugation of the culture at 4000 g for 20 minutes. Supernatant was then incubated with 6 mls Ni-
NTA agarose (Qiagen) for 1-2 hours at room temperature. Next, gravity flow columns were used to
collect the Ni-NTA agarose and the protein was eluted. Each protein was concentrated in Amicon

centrifugal units (EMD Millipore) and re-suspended in phosphate buffered saline (PBS). Proteins were
analyzed on reducing SDS-PAGE. The DNA sequence for all constructs is available from the Krammer
laboratory. Several of the expression plasmids and proteins have also been submitted to BEI Resources
and can be requested from their web page for free (https://www.beiresources.org/).
206
SDS-PAGE
Recombinant proteins were analyzed via a standard SDS-PAGE gel to check protein integrity. One ug of
protein was mixed with 2X Laemmli buffer containing 5% beta-mercaptoethanol (BME) at a ratio of 1:1.
Samples were heated at 100 °Celsius for 15 minutes and then loaded onto a polyacrylamide gel (5% to
20% gradient; Bio-Rad). Gels were stained with SimplyBlue SafeStain (Invitrogen) for 1-2 hours and then
de-stained in distilled water overnight.
213
214
Human samples
Banked human samples were collected from study participants enrolled in ongoing IRB approved
longitudinal observational study protocols of the Mount Sinai Personalized Virology Initiative. Samples
were selected based on the date of collection (2019, early 2020) and whether participants had a
documented history of viral infection. Samples were collected in the Clinical Research Unit at the Icahn
School of Medicine at Mount Sinai after obtaining written consent and all participants agreed to sample
banking and future research use. Self-reported ethnicities of the individuals from which samples were
tested included Caucasian, Asian, African American and Hispanic. Samples included sera from a
participant with acute NL63 infection as determined by the Biofire Respiratory panel. We included
serum collected at day 3 post symptom onset as well as convalescent serum from the same person (day
30 post symptom onset). In addition, we tested convalescent sera from individuals with dengue,
chikungunya and hantavirus infections. These samples served as negative controls given that they were
collect prior to SARS-Cov-2 spread in the US. Six subjects were 20-29, 19 were 30-39, 13 were 40-49, 7
were 50-59 years old and six were 60 or older. For the mRBD ELISAs sera from additional nine t subjects
were tested (30-39: 2; 40-49: 4; 50-59: 2; 60+: 1).
De-identified samples from the University of Melbourne and University of Helsinki were used as positive
controls. For those, human experimental work was conducted according to the Declaration of Helsinki
Principles and according to the Australian National Health and Medical Research Council Code of
Practice. All participants provided written informed consent prior to the study. The studies were
approved by the Alfred Hospital (ID #280/14) and University of Melbourne (ID #1442952.1, 1955465.2)
Human Research Ethics Committees, and under research permit for project TYH2018322 of Helsinki
University Hospital Laboratory.
237
ELISA
The ELISA protocol was adapted from previously established protocols [26,27]. Ninety-six well plates
(Immulon 4 HBX; Thermo Scientific) were coated overnight at 4°Celsius with 50 ul per well of a 2 ug/ml
solution of each respective protein suspended in PBS (Gibco). The next morning, the coating solution
was removed and 100 ul per well of 3% non-fat milk prepared in PBS with 0.1% Tween 20 (TPBS) was
added to the plates at room temperature (RT) for 1 hour as blocking solution. Serum samples were
heated at 56°C for 1 hour before use to reduce risk from any potential residual virus in serum. Serial
dilutions of serum and antibody samples were prepared in 1% non-fat milk prepared in TPBS. The
blocking solution was removed and 100 ul of each serial dilution was added to the plates for 2 hours at
RT. Next, the plates were washed thrice with 250ul per well of 0.1% TPBS. Next, a 1:3000 dilution of goat
anti-human IgG-horseradish peroxidase (HRP) conjugated secondary antibody (ThermoFisher
Scientific) was prepared in 0.1% TPBS and 100 ul of this secondary antibody was added to each well for 1

hour. Plates were again washed thrice with 0.1% TBS. Once completely dry, 100 ul of SigmaFast OPD (*o*-phenylenediamine dihydrochloride; Sigma-Aldrich) solution was added to each well. This substrate was left on the plates for 10 minutes and then the reaction was stopped by addition of 50 µL per well of 3 M hydrochloric acid (HCl). The optical density at 490 nanometers was measured via a Synergy 4 (BioTek) plate reader. The background value was set at and optical density 490nm of 0.11 and area under the curve (AUC) was calculated. AUC values below 1 were assigned a value of 0.5 for graphing and calculation purposes. Data was analyzed in Prism 7 (Graphpad).

To assess the distribution of the different antibody isotypes/subclasses in the samples that reacted well in our standard ELISA, another ELISA was performed with different secondary antibodies [23]. These antibodies include anti-human IgA (α-chain-specific) HRP antibody (Sigma A0295) (1:3,000), anti-human IgM (µ-chain-specific) HRP antibody (Sigma A6907) (1:3,000), anti-human IgG1 Fc-HRP (Southern Biotech 9054-05) (1:3,000), anti-human IgG3hinge-HRP (Southern Biotech 9210-05) (1:3,000), and anti-human IgG4 Fc-HRP (Southern Biotech 9200-05).

Acknowledgements

We would like to thank Yong-Zhen Zhang (Fudan University) and Eddie Holmes (University of Sydney) for sharing the sequence of the first SARS-CoV-2 isolate in a very timely manner. We thank Jill Garlick and Janine Roney (Alfred Hospital, Melbourne) for data and specimen collection. We are also thankful to Genewiz for speeding up gene synthesis for this project, and being very accommodating to our needs. Furthermore, we want to thank Donna Tidmore for help with ordering primers with near light speed and and finally Susie (Changsu) Dong for commuting to New Jersey on several occasions to pick up reagents from Genewiz. We also thank the study participants for providing biospecimen for research purposes and the Conduits: Mount Sinai Health System Translational Science Hub (NIH grant U54TR001433) for supporting sample collection. The work of the Personalized Virology Initiative is supported by institutional funds and philanthropic donations. This work was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C, the Australian National Health and Medical Research Council (NHMRC) NHMRC Program Grant (1071916) and NHMRC Research Fellowship Level B (#1102792), the Academy of Finland and Helsinki University Hospital Funds (TYH2018322). Finally, we want to thank the three COVID19 patients for their contribution to research and wish them a speedy recovery.

Conflict of interest

The authors declare no conflict of interest.

References

1.   Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020.

2.   Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020.

3.   Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory syndrome-related
coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology 2020.
4.   Chu DKW, Pan Y, Cheng SMS, et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV)
Causing an Outbreak of Pneumonia. Clin Chem 2020.
5.   Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-
time RT-PCR. Euro Surveill 2020;25.
6.   Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-
CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 2020.
7.   Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion
conformation. Science 2020.
8.   Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and
Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020.
9.   Berry JD, Hay K, Rini JM, et al. Neutralizing epitopes of the SARS-CoV S-protein cluster
independent of repertoire, antigen structure or mAb technology. MAbs 2010;2:53-66.
10.   Liu W, Fontanet A, Zhang PH, et al. Two-year prospective study of the humoral immune
response of patients with severe acute respiratory syndrome. J Infect Dis 2006;193:792-5.
11.   Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to
experimental coronavirus infection of man. Epidemiol Infect 1990;105:435-46.
12.   Choe PG, Perera RAPM, Park WB, et al. MERS-CoV Antibody Responses 1 Year after Symptom
Onset, South Korea, 2015. Emerg Infect Dis 2017;23:1079-84.
13.   Haveri A, Smura T, Kuivanen S, et al. Serological and molecular findings during SARS-CoV-2
infection: the first case study in Finland, January to February 2020. Eurosurveillance2020.
14.   Pallesen J, Wang N, Corbett KS, et al. Immunogenicity and structures of a rationally designed
prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A 2017;114:E7348-E57.
15.   Kirchdoerfer RN, Cottrell CA, Wang N, et al. Pre-fusion structure of a human coronavirus spike
protein. Nature 2016;531:118-21.
16.   Krammer F, Margine I, Tan GS, Pica N, Krause JC, Palese P. A carboxy-terminal trimerization
domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin
substrates. PLoS One 2012;7:e43603.
17.   Margine I, Palese P, Krammer F. Expression of Functional Recombinant Hemagglutinin and
Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System. J
Vis Exp 2013.
18.   Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain
complexed with receptor. Science 2005;309:1864-8.
19.   Wu K, Li W, Peng G, Li F. Crystal structure of NL63 respiratory coronavirus receptor-binding
domain complexed with its human receptor. Proc Natl Acad Sci U S A 2009;106:19970-4.
20.   Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-
Infected Pneumonia. N Engl J Med 2020.
21.   Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus vaccines
leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 2012;7:e35421.
22.   Nachbagauer R, Choi A, Izikson R, Cox MM, Palese P, Krammer F. Age Dependence and Isotype
Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. MBio 2016;7.
23.   Rajendran M, Nachbagauer R, Ermler ME, et al. Analysis of Anti-Influenza Virus Neuraminidase
Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original
Antigenic Sin. MBio 2017;8.
24.   Amanat F, Duehr J, Oestereich L, Hastie KM, Ollmann Saphire E, Krammer F. Antibodies to the
Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses. mSphere 2018;3.

25.   Margine I, Palese P, Krammer F. Expression of functional recombinant hemagglutinin and
neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J
Vis Exp 2013:e51112.
26.   Amanat F, Meade P, Strohmeier S, Krammer F. Cross-reactive antibodies binding to H4
hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model. Emerg
Microbes Infect 2019;8:155-68.
27.   Wohlbold TJ, Podolsky KA, Chromikova V, et al. Broadly protective murine monoclonal
antibodies against influenza B virus target highly conserved neuraminidase epitopes. Nat Microbiol
2017;2:1415-24.

Figure legends

Figure 1: Constructs for recombinant protein expression. A Visualization of the trimeric spike protein of
SARS-CoV-2 based on PBD # 6VXX using Pymol.[8] One monomer is colored in dark blue while the
remaining two monomers are held in light blue. The receptor binding domain (RBD) of the dark blue
trimer is highlighted in red. **B** Schematic of the wild type full length spike protein with signal peptide,
ectodomain, receptor binding domain, furin cleavage site, S1, S2, and transmembrane and endodomain
domain indicated. **C** Schematic of the soluble trimeric spike. The polybasic/furin cleavage site (RRAR)
was replaced by a single A. The transmembrane and endodomain were replaced by a furin cleavage site,
a T4 foldon tetramerization domain and a hexahistidine tag. Introduction of K986P and V987P has been
shown to stabilize the trimer in the pre-fusion conformation. **D** Schematic of the soluble receptor
binding domain construct. All constructs are to scale. **E** Reducing SDS PAGE of insect cell and mammalian
cell derived soluble trimerized spike protein (iSpike and rSpike). **F** Reducing SDS PAGE of insect cell
derived and mammalian cell derived recombinant receptor binding domain (iRBD and mRBD).

Figure 2: Reactivity of control and SARS-CoV-2 convalescent sera to different spike antigens. A-D
Reactivity to insect cell derived RBD (iRBD), mammalian cell derived RBD (mRBD), insect cell derived
soluble spike protein (iSpike) and mammalian cell derived soluble spike protein (sSpike). Sera from three
SARS-CoV-2 infected individuals were used and are shown in shades of red. Two samples are from the
same patient but from different time points (SARS-CoV-2 #3A and #3B). One sample, shown in green, is
a convalescent serum sample post NL63 infection. **E-F** shows data from the same experiment but
graphed as area under the curve (AUC) to get a better quantitative impression. The n for the control
samples is 50 except for the iRBD were it is 59. Statistics were performed using a student's t-test in
Graphpad Prism.

Figure 3: Isotypes and subtypes of antibodies from SARS-CoV-2 convalescent sera to the soluble spike
protein. Insect cell derived (**A**) and mammalian cell derived (**B**) spike protein was used to study
isotype/subclass distribution of antibodies. The different samples are indicated by different symbols.
Sera from three SARS-CoV-2 infected individuals were used and are shown in shades of red. Two
samples are from the same patient but from different time points (SARS-CoV-2 #3A and #3B).

A

Receptor binding domain
(amino acid 319-541)

Membrane distal

Membrane proximal

E   ladder   iSpike   mSpike

245 kDa
190 kDa
135 kDa
100 kDa
80 kDa
58 kDa
46 kDa
32 kDa
25 kDa
22 kDa
17 kDa

F   ladder   iRBD   mRBD

B   Wild type spike

N

Receptor binding domain
(amino acid 319-541)

S1 ← Polybasic cleaveage site → S2
(amino acid 682-685/RRAR)

P1213   N

Signal peptide
(amino acid 1-14)

Ectodomain
(amino acid 15-1213)

Transmembrane- and endodomain
(amino acid 1214-1273)

C   Stabilized, soluble spike

RRAR to A   K986P and V987P

Signal peptide
(amino acid 1-14)

Ectodomain
(amino acid 15-1213)

Thrombin cleavage site, T4 trimerization domain and 6xhis tag

D   Soluble receptor binding domain

Signal peptide
(amino acid 1-14)

Receptor binding domain
(amino acid 319-541)

6xhis tag